The Week in Review: Big Week for China Pharma IPOs

Sihuan Pharma Holdings priced its IPO at the top of its range, raising $741 million; before the transaction, New Horizon Capital was forced to sell its $80 million investment in Sihuan back to the company because of suspected favoritism; Shanghai Pharma will stage a $1.5 billion Hong Kong IPO next year; CRO ShangPharma completed its IPO on the NYSE; China’s 12th Five-Year Plan will consolidate the country’s drug distributors into one or two players on the national level; Pfizer struck a $350 million deal with Biocon of India for diabetes biosimilars; Takeda Pharma of Japan acquired the remaining 25% of its China JV; Livzon Pharma will develop a $300 million bio-tech park in Guangdong Province; and ProMetic Life Sciences enlisted Shanghai Allist Pharma to develop two of ProMetic's drug candidates in China. More details…. Stock Symbols: (HKEX: 0460) (SHEX: 601607) (NYSE: SHP) (NYSE: PFE) (TO: 4502) (SHEN: 000513) (TSX: PLI)